Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirdametinib Alone or With Radiotherapy for NF1-Altered High-Grade Glioma
NCT07521657Phase 2Not yet recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Jan 2027
- Primary completion
- Jan 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of mirdametinib in glioblastoma (GBM), glioma and high-grade astrocytoma with piloid features (HGAP) (3 cohorts), sponsored by University of Alabama at Birmingham. Primary endpoint: Radiographic Response by RANO 2.0 Criteria at 18 months. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
mirdametinib
03
Conditions
glioblastoma (GBM)gliomahigh-grade astrocytoma with piloid features (HGAP)
Beyond the preview
Go deeper on NCT07521657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07521657.